{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:14:27Z","timestamp":1788214467431,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82200253"],"award-info":[{"award-number":["82200253"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470194"],"award-info":[{"award-number":["82470194"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82402821"],"award-info":[{"award-number":["82402821"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Burrough Welcome Fund \u2013 Career Award for Medicine Scientists"},{"name":"Penn Center for Targeted Therapeutics and Translational Nanomedicine (CT3N) Pilot Grant"},{"name":"National Center for Advancing Translational Sciences of the National Institutes of Health","award":["UL1TR001878"],"award-info":[{"award-number":["UL1TR001878"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFC2502604"],"award-info":[{"award-number":["2022YFC2502604"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2024-I2M-3-021"],"award-info":[{"award-number":["2024-I2M-3-021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00749-5","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:46:28Z","timestamp":1770464788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Engineered extracellular vesicles displaying bi-specific T-cell engagers for targeted therapy of B-cell malignancies"],"prefix":"10.1186","volume":"15","author":[{"given":"Xiuxiu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3841-0174","authenticated-orcid":false,"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7219-9798","authenticated-orcid":false,"given":"Caroline","family":"Markmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2858-0962","authenticated-orcid":false,"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2857-4092","authenticated-orcid":false,"given":"Vijay G.","family":"Bhoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-3232","authenticated-orcid":false,"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3242-5738","authenticated-orcid":false,"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"4","key":"749_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.14740\/jh1112","volume":"12","author":"N Visweshwar","year":"2023","unstructured":"Visweshwar N, Rico JF, Killeen R, Manoharan A. Harnessing the immune system: an effective way to manage diffuse large B-Cell lymphoma. J Hematol. 2023;12(4):145\u201360.","journal-title":"J Hematol"},{"issue":"4","key":"749_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"14","key":"749_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1182\/blood.2023022922","volume":"145","author":"A Rampotas","year":"2025","unstructured":"Rampotas A, Roddie C. The present and future of CAR T-cell therapy for adult B-cell ALL. Blood. 2025;145(14):1485\u201397.","journal-title":"Blood"},{"issue":"1","key":"749_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41392-023-01523-3","volume":"8","author":"X-m Yang","year":"2023","unstructured":"Yang X-m, Lin X-d, Shi W, Xie S-x, Huang X-n, Yin S-h, et al. Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy. Signal Transduct Target Therapy. 2023;8(1):328.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"749_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14(1):75.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"749_CR6","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1038\/s41467-024-49495-4","volume":"15","author":"ZX Yan","year":"2024","unstructured":"Yan ZX, Dong Y, Qiao N, Zhang YL, Wu W, Zhu Y, et al. Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma. Nat Commun. 2024;15(1):5183.","journal-title":"Nat Commun"},{"issue":"1","key":"749_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15(1):61.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"749_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"Z-D Shi","year":"2023","unstructured":"Shi Z-D, Pang K, Wu Z-X, Dong Y, Hao L, Qin J-X, et al. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Therapy. 2023;8(1):113.","journal-title":"Signal Transduct Target Therapy"},{"issue":"8048","key":"749_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025;637(8048):1207\u201317.","journal-title":"Nature"},{"issue":"1","key":"749_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","volume":"29","author":"A Tiwari","year":"2022","unstructured":"Tiwari A, Trivedi R, Lin SY. Tumor microenvironment: barrier or opportunity towards effective cancer therapy. J Biomed Sci. 2022;29(1):83.","journal-title":"J Biomed Sci"},{"issue":"4","key":"749_CR11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41587-025-02597-w","volume":"43","author":"X Yuan","year":"2025","unstructured":"Yuan X, Xiao Y, Yu D. Turn cold tumors hot by reprogramming the tumor microenvironment. Nat Biotechnol. 2025;43(4):466\u201370.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"749_CR12","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022;28(9):1872\u201382.","journal-title":"Nat Med"},{"issue":"8","key":"749_CR13","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","volume":"186","author":"R Kalluri","year":"2023","unstructured":"Kalluri R, McAndrews KM. The role of extracellular vesicles in cancer. Cell. 2023;186(8):1610\u201326.","journal-title":"Cell"},{"issue":"7","key":"749_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","volume":"16","author":"IK Herrmann","year":"2021","unstructured":"Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16(7):748\u201359.","journal-title":"Nat Nanotechnol"},{"issue":"7","key":"749_CR15","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nnano.2017.52","volume":"12","author":"M Luo","year":"2017","unstructured":"Luo M, Wang H, Wang Z, Cai H, Lu Z, Li Y, et al. A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnol. 2017;12(7):648\u201354.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"749_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","volume":"18","author":"M Shen","year":"2025","unstructured":"Shen M, Jiang X, Peng Q, Oyang L, Ren Z, Wang J, et al. The cGAS\u2013STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications. J Hematol Oncol. 2025;18(1):40.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"749_CR17","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/s41551-025-01400-0","volume":"9","author":"BR Kimmel","year":"2025","unstructured":"Kimmel BR, Arora K, Chada NC, Bharti V, Kwiatkowski AJ, Finkelstein JE, et al. Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody\u2013STING agonist conjugates. Nat Biomed Eng. 2025;9(10):1719\u201339.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"749_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/cts.12877","volume":"14","author":"PN Morcos","year":"2021","unstructured":"Morcos PN, Li J, Hosseini I, Li CC. Quantitative clinical Pharmacology of T-Cell engaging bispecifics: current perspectives and opportunities. Clin Transl Sci. 2021;14(1):75\u201385.","journal-title":"Clin Transl Sci"},{"issue":"12","key":"749_CR19","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022;3(12):1452\u201363.","journal-title":"Nat Cancer"},{"issue":"1","key":"749_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","volume":"19","author":"Y Wang","year":"2020","unstructured":"Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19(1):136.","journal-title":"Mol Cancer"},{"issue":"2","key":"749_CR21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.immuni.2023.01.010","volume":"56","author":"M Zagorulya","year":"2023","unstructured":"Zagorulya M, Yim L, Morgan DM, Edwards A, Torres-Mejia E, Momin N, et al. Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. Immunity. 2023;56(2):386\u2013e40510.","journal-title":"Immunity"},{"issue":"10","key":"749_CR22","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.immuni.2023.07.018","volume":"56","author":"LL Cao","year":"2023","unstructured":"Cao LL, Kagan JC. Targeting innate immune pathways for cancer immunotherapy. Immunity. 2023;56(10):2206\u201317.","journal-title":"Immunity"},{"issue":"4","key":"749_CR23","doi-asserted-by":"publisher","first-page":"101479","DOI":"10.1016\/j.xcrm.2024.101479","volume":"5","author":"RJ Lim","year":"2024","unstructured":"Lim RJ, Salehi-Rad R, Tran LM, Oh MS, Dumitras C, Crosson WP, et al. CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint Blockade for lung cancer. Cell Rep Med. 2024;5(4):101479.","journal-title":"Cell Rep Med"},{"issue":"10","key":"749_CR24","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.3390\/jcm9103323","volume":"9","author":"L Motedayen Aval","year":"2020","unstructured":"Motedayen Aval L, Pease JE, Sharma R, Pinato DJ. Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J Clin Med. 2020;9(10):3323.","journal-title":"J Clin Med"},{"issue":"7","key":"749_CR25","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1021\/acs.accounts.9b00109","volume":"52","author":"OG de Jong","year":"2019","unstructured":"de Jong OG, Kooijmans SAA, Murphy DE, Jiang L, Evers MJW, Sluijter JPG, et al. Drug delivery with extracellular vesicles: from imagination to innovation. Acc Chem Res. 2019;52(7):1761\u201370.","journal-title":"Acc Chem Res"},{"issue":"4","key":"749_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of SiRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341\u20135.","journal-title":"Nat Biotechnol"},{"key":"749_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jconrel.2020.07.033","volume":"326","author":"Q Xu","year":"2020","unstructured":"Xu Q, Zhang Z, Zhao L, Qin Y, Cai H, Geng Z, et al. Tropism-facilitated delivery of CRISPR\/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies. J Control Release. 2020;326:455\u201367.","journal-title":"J Control Release"},{"key":"749_CR28","doi-asserted-by":"publisher","first-page":"100523","DOI":"10.1016\/j.jbc.2021.100523","volume":"296","author":"KM McAndrews","year":"2021","unstructured":"McAndrews KM, Che SPY, LeBleu VS, Kalluri R. Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity. J Biol Chem. 2021;296:100523.","journal-title":"J Biol Chem"},{"issue":"1","key":"749_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s42003-021-02004-5","volume":"4","author":"SC Jang","year":"2021","unstructured":"Jang SC, Economides KD, Moniz RJ, Sia CL, Lewis N, McCoy C, et al. ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance. Commun Biol. 2021;4(1):497.","journal-title":"Commun Biol"},{"issue":"6","key":"749_CR30","doi-asserted-by":"publisher","first-page":"e2306336","DOI":"10.1002\/advs.202306336","volume":"11","author":"P Bao","year":"2024","unstructured":"Bao P, Gu HY, Ye JJ, He JL, Zhong Z, Yu AX, et al. Chimeric exosomes functionalized with STING activation for personalized glioblastoma immunotherapy. Adv Sci (Weinh). 2024;11(6):e2306336.","journal-title":"Adv Sci (Weinh)"},{"issue":"127","key":"749_CR31","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.","journal-title":"Sci Transl Med"},{"issue":"1","key":"749_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41590-025-02337-x","volume":"27","author":"K Mulder","year":"2026","unstructured":"Mulder K, Gardet M, Kong WT, Patel AA, Calvez A, Gessain G, et al. DC subsets and States unraveled across human juxtatumoral and malignant tissues. Nat Immunol. 2026;27(1):135\u201349.","journal-title":"Nat Immunol"},{"issue":"2","key":"749_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s43018-025-00909-2","volume":"6","author":"R Jin","year":"2025","unstructured":"Jin R, Neufeld L, McGaha TL. Linking macrophage metabolism to function in the tumor microenvironment. Nat Cancer. 2025;6(2):239\u201352.","journal-title":"Nat Cancer"},{"issue":"12","key":"749_CR34","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/s41556-025-01815-6","volume":"27","author":"J Liu","year":"2025","unstructured":"Liu J, Qu C, Liu Y, Gongye X, Zhang M, Ma T, et al. WDR4 drives tumour-associated macrophage reprogramming and tumour progression via selective translation and membrane cholesterol efflux. Nat Cell Biol. 2025;27(12):2152\u201366.","journal-title":"Nat Cell Biol"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00749-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00749-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00749-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:04:27Z","timestamp":1771275867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00749-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00749-5","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Z.Z. and Q.X. are inventors on a granted patent (CN116083369B) related to the CD19\u00d7CD3 BiTE EVs platform. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}